Citigroup’s Ocular Therapeutix OCUL Stock Holding History

Citigroup’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,700	Closed	-$20K	–	7761
2019 Q3	$20K	Buy	+6,700	New	+$30K	﹤0.01%	6738
2019 Q2	–	Sell	-7,700	Closed	-$31K	–	7822
2019 Q1	$31K	Sell	7,700 -6,500	-46%	-$26.1K	﹤0.01%	6717
2018 Q4	$57K	Buy	14,200 +13,500	+1,929%	+$74.4K	﹤0.01%	6126
2018 Q3	$5K	Sell	700 -2,100	-75%	-$13.2K	﹤0.01%	7496
2018 Q2	$19K	Sell	2,800 -4,400	-61%	-$30.2K	﹤0.01%	6945
2018 Q1	$47K	Hold	7,200	–	–	﹤0.01%	6213
2017 Q4	$32K	Buy	7,200 +5,800	+414%	+$29.6K	﹤0.01%	6471
2017 Q3	$9K	Sell	1,400 -5,600	-80%	-$36.1K	﹤0.01%	6724
2017 Q2	$65K	Buy	7,000 +1,200	+21%	+$11.6K	﹤0.01%	5617
2017 Q1	$54K	Buy	+5,800	New	+$48.3K	﹤0.01%	5641

Other funds holding OCUL

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Kraematon Investment Advisors Braintree, Massachusetts $134M AUM 18.69% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return

Citigroup's OCUL Position: Q3 2026 in Review

Citigroup reduced its Ocular Therapeutix (OCUL) stake by 53% in Q3 2026, selling an estimated $732K and leaving 65,898 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #3754.

Citigroup first reported a position in OCUL in Q3 2014 and has held it in 47 quarters since. The position peaked at $7.87M in Q3 2025. 66 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

Citigroup held 65,898 shares of Ocular Therapeutix worth $505K as of Q3 2026.
Citigroup sold 74,820 Ocular Therapeutix shares in Q3 2026, an estimated $732K.
Ocular Therapeutix made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3754 holding.
Citigroup first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 47 quarters since.
Citigroup's Ocular Therapeutix position peaked at $7.87M in Q3 2025.
66 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.